Literature DB >> 24905297

An experimental cell-based model for studying the cell biology and molecular pharmacology of 5-lipoxygenase-activating protein in leukotriene biosynthesis.

Jana Gerstmeier1, Christina Weinigel2, Dagmar Barz2, Oliver Werz1, Ulrike Garscha1.   

Abstract

BACKGROUND: Subcellular distribution of 5-lipoxygenase (5-LO) to the perinuclear region and interaction with the 5-LO-activating protein (FLAP) are assumed as key steps in leukotriene biosynthesis and are prone to FLAP antagonists.
METHODS: FLAP and/or 5-LO were stably expressed in HEK293 cells, 5-LO products were analyzed by HPLC, and 5-LO and FLAP subcellular localization was visualized by immunofluorescence microscopy.
RESULTS: 5-LO and FLAP were stably expressed in HEK293 cells, and upon Ca(2+)-ionophore A23187 stimulation exogenous AA was efficiently transformed into the 5-LO products 5-hydro(pero)xyeicosatetraenoic acid (5-H(p)ETE) and the trans-isomers of LTB4. A23187 stimulation caused 5-LO accumulation at the nuclear membrane only when FLAP was co-expressed. Unexpectedly, A23187 stimulation of HEK cells expressing 5-LO and FLAP without exogenous AA failed in 5-LO product synthesis. HEK cells liberated AA in response to A23187, and transfected HEK cells expressing 12-LO generated 12-HETE after A23187 challenge from endogenous AA. FLAP co-expression increased 5-LO product formation in A23187-stimulated cells at low AA concentrations. Only in cells expressing FLAP and 5-LO, the FLAP antagonist MK886 blocked FLAP-mediated increase in 5-LO product formation, and prevented 5-LO nuclear membrane translocation and co-localization with FLAP.
CONCLUSION: The cellular biosynthesis of 5-LO products from endogenously derived substrate requires not only functional 5-LO/FLAP co-localization but also additional prerequisites which are dispensable when exogenous AA is supplied; identification of these determinants is challenging. GENERAL SIGNIFICANCE: We present a cell model to study the role of FLAP as 5-LO interacting protein in LT biosynthesis in intact cells and for characterization of putative FLAP antagonists.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  12-Lipoxygenase; 5-Lipoxygenase; 5-Lipoxygenase-activating protein; Arachidonic acid; HEK293 cells; MK886

Mesh:

Substances:

Year:  2014        PMID: 24905297     DOI: 10.1016/j.bbagen.2014.05.016

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  13 in total

1.  Membrane-dependent Activities of Human 15-LOX-2 and Its Murine Counterpart: IMPLICATIONS FOR MURINE MODELS OF ATHEROSCLEROSIS.

Authors:  Gunes Bender; Erin E Schexnaydre; Robert C Murphy; Charis Uhlson; Marcia E Newcomer
Journal:  J Biol Chem       Date:  2016-07-19       Impact factor: 5.157

2.  Identification of the Substrate Access Portal of 5-Lipoxygenase.

Authors:  Sunayana Mitra; Sue G Bartlett; Marcia E Newcomer
Journal:  Biochemistry       Date:  2015-10-08       Impact factor: 3.162

3.  Strict Regiospecificity of Human Epithelial 15-Lipoxygenase-2 Delineates Its Transcellular Synthesis Potential.

Authors:  Abigail R Green; Shannon Barbour; Thomas Horn; Jose Carlos; Jevgenij A Raskatov; Theodore R Holman
Journal:  Biochemistry       Date:  2016-05-13       Impact factor: 3.162

4.  Structural and mechanistic insights into 5-lipoxygenase inhibition by natural products.

Authors:  Nathaniel C Gilbert; Jana Gerstmeier; Erin E Schexnaydre; Friedemann Börner; Ulrike Garscha; David B Neau; Oliver Werz; Marcia E Newcomer
Journal:  Nat Chem Biol       Date:  2020-05-11       Impact factor: 15.040

5.  A 5‑lipoxygenase-specific sequence motif impedes enzyme activity and confers dependence on a partner protein.

Authors:  Erin E Schexnaydre; Jana Gerstmeier; Ulrike Garscha; Paul M Jordan; Oliver Werz; Marcia E Newcomer
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-10-03       Impact factor: 4.698

6.  5-Lipoxygenase-activating protein rescues activity of 5-lipoxygenase mutations that delay nuclear membrane association and disrupt product formation.

Authors:  Jana Gerstmeier; Marcia E Newcomer; Sophie Dennhardt; Erik Romp; Jana Fischer; Oliver Werz; Ulrike Garscha
Journal:  FASEB J       Date:  2016-02-03       Impact factor: 5.191

7.  The Intracellular Localisation and Phosphorylation Profile of the Human 5-Lipoxygenase Δ13 Isoform Differs from That of Its Full Length Counterpart.

Authors:  Eric P Allain; Luc H Boudreau; Nicolas Flamand; Marc E Surette
Journal:  PLoS One       Date:  2015-07-14       Impact factor: 3.240

8.  Pharmacological profile and efficiency in vivo of diflapolin, the first dual inhibitor of 5-lipoxygenase-activating protein and soluble epoxide hydrolase.

Authors:  Ulrike Garscha; Erik Romp; Simona Pace; Antonietta Rossi; Veronika Temml; Daniela Schuster; Stefanie König; Jana Gerstmeier; Stefanie Liening; Markus Werner; Heiner Atze; Sandra Wittmann; Christina Weinigel; Silke Rummler; Gerhard K Scriba; Lidia Sautebin; Oliver Werz
Journal:  Sci Rep       Date:  2017-08-24       Impact factor: 4.379

9.  New Hydroxycinnamic Acid Esters as Novel 5-Lipoxygenase Inhibitors That Affect Leukotriene Biosynthesis.

Authors:  Luc H Boudreau; Grégoire Lassalle-Claux; Marc Cormier; Sébastien Blanchard; Marco S Doucet; Marc E Surette; Mohamed Touaibia
Journal:  Mediators Inflamm       Date:  2017-06-07       Impact factor: 4.711

10.  CD64 and Group II Secretory Phospholipase A2 (sPLA2-IIA) as Biomarkers for Distinguishing Adult Sepsis and Bacterial Infections in the Emergency Department.

Authors:  Toh Leong Tan; Nurul Saadah Ahmad; Dian Nasriana Nasuruddin; Azlin Ithnin; Khaizurin Tajul Arifin; Ida Zarina Zaini; Wan Zurinah Wan Ngah
Journal:  PLoS One       Date:  2016-03-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.